{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:26:37Z","timestamp":1787739997589,"version":"build-2784847793"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,11]],"date-time":"2009-10-11T00:00:00Z","timestamp":1255219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We analysed 1221 serum activity measurements in 168 children from the Berlin\u2010Frankf\u00fcrt\u2010M\u00fcnster acute lymphoblastic leukaemia studies, ALL\u2010BFM (Berlin\u2010Frankf\u00fcrt\u2010M\u00fcnster) 95 and ALL\u2010BFM REZ, in order to develop a pharmacokinetic model describing the activity\u2010time course of pegylated (PEG)\u2010asparaginase for all dose levels. Patients received 500, 750, 1000 or 2500\u2003U\/m<jats:sup>2<\/jats:sup>PEG\u2010asparaginase on up to nine occasions. Serum samples were analysed for asparaginase activity and data analysis was done using nonlinear mixed effects modelling (NONMEM Vers. VI, Globomax, Hanouet, MD, USA). Different linear and nonlinear models were tested. The best model applicable to all dosing groups was a one\u2010compartmental model with clearance (Cl) increasing with time according to the formula: Cl=Cl<jats:sub>i<\/jats:sub>\u2003*<jats:italic>e<\/jats:italic><jats:sup>(0\u00b70793\u2003*<jats:italic>t<\/jats:italic>)<\/jats:sup>where Cl<jats:sub>i<\/jats:sub>\u2003=\u2003initial clearance and<jats:italic>t\u2003<\/jats:italic>=\u2003time after dose. The parameters found were: volume of distribution (<jats:italic>V<\/jats:italic>) 1\u00b702\u2003\u00b1\u200326%\u2003l\/m<jats:sup>2<\/jats:sup>, Cl<jats:sub>i<\/jats:sub>59\u00b79\u2003\u00b1\u200359%\u2003ml\/d per m<jats:sup>2<\/jats:sup>(mean\u2003\u00b1\u2003interindividual variability). Interoccasion variability was substantial with 0\u00b7183\u2003l\/m<jats:sup>2<\/jats:sup>for<jats:italic>V<\/jats:italic>and 44\u00b77\u2003ml\/d per m<jats:sup>2<\/jats:sup>for Cl, respectively. A subgroup of the patients showed a high clearance, probably due to the development of inactivating antibodies. This is the first model able to predict the activity\u2010time course of PEG\u2010asparaginase at different dosing levels and can therefore be used for developing new dosing regimens.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2009.07923.x","type":"journal-article","created":{"date-parts":[[2009,10,12]],"date-time":"2009-10-12T04:06:28Z","timestamp":1255320388000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A population pharmacokinetic model for pegylated\u2010asparaginase in children"],"prefix":"10.1111","volume":"148","author":[{"given":"Georg","family":"Hempel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans\u2010Joachim","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lanvers\u2010Kaminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"W\u00fcrthwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Boos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,14]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22739"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00003"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318047b79d"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.1986"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.9.2474"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90113-7"},{"key":"e_1_2_5_10_1","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/jama.1967.03130220070012","article-title":"l\u2010asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia","volume":"202","author":"Hill J.M.","year":"1967","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_5_11_1","first-page":"1574","article-title":"Response to highly purified l\u2010asparaginase during therapy of acute leukemia","volume":"29","author":"Hill J.M.","year":"1969","journal-title":"Cancer Research"},{"key":"e_1_2_5_12_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0090-9556(25)08348-5","article-title":"Clinical pharmacology of polyethylene glycol\u2010l\u2010asparaginase","volume":"14","author":"Ho D.H.","year":"1986","journal-title":"Drug Metabolism and Disposition"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01113502"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-2697(02)00232-4"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(98)00015-8"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02187.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-001-0391-5"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-6-3"},{"key":"e_1_2_5_19_1","first-page":"4554","article-title":"l\u2010asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans","volume":"41","author":"Riccardi R.","year":"1981","journal-title":"Cancer Research"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000015853"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-872516"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2009.07923.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2009.07923.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T18:08:21Z","timestamp":1739383701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2009.07923.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2141.2009.07923.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07923.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,14]]},"assertion":[{"value":"2009-12-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}